Related Experiment Video
Updated: Aug 7, 2026
07:16
Thermal Ablation for the Treatment of Abdominal Tumors
Published on: March 7, 2011
Probe-ablative nephron-sparing surgery: cryoablation versus radiofrequency ablation
Nicholas J Hegarty1, Inderbir S Gill, Mihir M Desai
1Section of Laparoscopic and Robotic Surgery, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. kaoukj@ccf.org
Urology
|July 22, 2006
Summary
Cryoablation and radiofrequency ablation (RFA) are effective treatments for localized kidney tumors, showing similar tumor sizes but differing in tumor location and kidney status. Both methods offer low complication rates and preserve renal function, with encouraging early oncologic outcomes.
Area of Science:
- Urology
- Oncology
- Minimally Invasive Surgery
Background:
- Probe ablative therapies like cryoablation and radiofrequency ablation (RFA) are emerging treatments for localized renal tumors.
- These techniques aim to preserve kidney function while treating cancerous growths.
Purpose of the Study:
- To retrospectively compare the safety and efficacy of laparoscopic cryoablation and percutaneous RFA for localized renal tumors.
- To evaluate complications, renal function impact, imaging follow-up, and oncologic outcomes between the two ablation methods.
Main Methods:
- Retrospective comparison of 164 laparoscopic cryoablations and 82 percutaneous RFAs.
- Data collected on tumor characteristics, treatment parameters, complications, renal function (serum creatinine), and oncologic outcomes.
Main Results:
- Similar mean tumor size (2.56 cm vs 2.51 cm) between cryoablation and RFA groups.
- Cryoablation had more anterior tumors (39% vs 10%) and fewer central tumors (6% vs 37%) compared to RFA.
- Lower recurrence/persistence rates with cryoablation (1.8%) versus RFA (11.1%), with minimal impact on renal function and low complication rates for both.
Conclusions:
- Both cryoablation and RFA are promising nephron-sparing options for renal tumors.
- Early oncologic control, preserved renal function, and low complication rates are encouraging for both modalities.
- Longer-term data are needed to fully ascertain the value of these ablative therapies.
